Association between Site-of-Care and the Cost and Modality of Radiotherapy for Prostate Cancer: Analysis of Medicare Beneficiaries from 2015 to 2017

Cancer Invest. 2021 Feb;39(2):144-152. doi: 10.1080/07357907.2020.1865396. Epub 2021 Jan 8.

Abstract

Among 84,447 radiotherapy (RT) courses for Medicare beneficiaries age ≥ 65 with prostate cancer treated with external beam RT (EBRT), brachytherapy, or both, 42,608 (51%) were delivered in hospital-affiliated and 41,695 (49%) in freestanding facilities. Freestanding centers were less likely to use EBRT + brachytherapy than EBRT (OR 0.84 [95%CI 0.84-0.84]; p < .001). Treatment was more costly in freestanding centers (mean difference $2,597 [95%CI $2,475-2,719]; p < .001). Adjusting for modality and fractionation, RT in hospital-affiliated centers was more costly (mean difference $773 [95%CI $693-853]; p < .001). Freestanding centers utilized more expensive RT delivery, but factors unrelated to RT modality or fractionation rendered RT more costly at hospital-affiliated centers.

Keywords: Prostate cancer; episode-based payment; radiation oncology; site-neutrality.

Publication types

  • Comparative Study

MeSH terms

  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Brachytherapy / economics*
  • Combined Modality Therapy / economics
  • Cross-Sectional Studies
  • Health Facilities / classification
  • Health Facilities / economics*
  • Humans
  • Male
  • Medicare
  • Prostatic Neoplasms / economics
  • Prostatic Neoplasms / radiotherapy*
  • Proton Therapy / economics*
  • United States